Get the Stockscreener App
15.90
0.13%
-0.02
Pre-market:
16.05
0.15
+0.94%
Rallybio Corp stock is traded at $15.90, with a volume of 138.59K.
It is down -0.13% in the last 24 hours and up +11.19% over the past month.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
See More
Previous Close:
$15.92
Open:
$15.86
24h Volume:
138.59K
Relative Volume:
0.56
Market Cap:
$92.22M
Revenue:
$858.00K
Net Income/Loss:
$-7.82M
P/E Ratio:
-10.96
EPS:
-1.4503
Net Cash Flow:
$-27.59M
1W Performance:
-0.06%
1M Performance:
+11.19%
6M Performance:
+158.35%
1Y Performance:
+513.43%
1-Day Range:
$15.84
$16.45
1-Week Range:
$15.76
$16.50
52-Week Range:
$2.40
$17.57
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
15.90 | 92.22M | 858.00K | -7.82M | -27.59M | -1.4503 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - Stocktwits
RLYB stock hits 2-year highs after unveiling merger with Avenzo – how much of the new company will Rallybio shareholders own? - MSN
Rallybio Company Profile & Introduction - Moomoo
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
JOHNSON & JOHNSON's Rallybio Corp(RLYB) Holding History - GuruFocus
San Diego Biotech Upstart Avenzo Plots Nasdaq Splash In Rallybio Reverse Merger - Hoodline
United StatesMintz Advising On $215 Million Private Placement Concurrent With Avenzo Therapeutics’ And Rallybio’s Merger Transaction - Mondaq
Avenzo Picks Up Reverse Merger Ditched by Candid - San Diego Business Journal
ADAR1, Daniel Schneeberger disclose 17.5% stake in Rallybio (RLYB) - Stock Titan
RLYB Stock Chart | RALLYBIO CORP (NASDAQ:RLYB) - ChartMill
Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock - Investing.com
Mintz Advising on $215 Million Private Placement Concurrent with Avenzo Therapeutics’ and Rallybio’s Merger Transaction - Mintz
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio CorporationRLYB - Business Wire
Shareholder Alert: Ademi LLP investigates whether Rallybio Corpo - GuruFocus
Halper Sadeh LLC is Investigating Whether RLYB, KALV, INM, TMHC are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders - PR Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Rallybio, Avenzo agree oncology reverse merger backed by $215 million financing - The Pharma Letter
Rallybio to Raise $215M Via Pvt Placement >RLYB - Moomoo
Rallybio: Placement Expected to Fund Ops Into Late 2028 >RLYB - Moomoo
Rallybio: Combined Co Expected to Operate As Avenzo Therapeutics >RLYB - Moomoo
RLYB: Merger leverages oncology expertise and $215M funding to advance clinical programs and milestones - TradingView
RLYB: Merger accelerates oncology pipeline with $215M funding and late 2028 cash runway - TradingView
Rallybio finds a new reverse-merger dance partner in Avenzo - FirstWord Pharma
RallyBio tries again for reverse merger, this time with Avenzo - BioPharma Dive
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders - marketscreener.com
RLYB: Rallybio to Merge with Avenzo Therapeutics in Strategic Ac - GuruFocus
EDGAR Filing Documents for 0001193125-26-249801 - SEC.gov
Rallybio and Avenzo Therapeutics Announce Merger and $215 Million Private Placement to Advance Next-Generation Oncology Therapies – Minichart - Minichart
Rallybio to merge with Avenzo Therapeutics in $215M deal - grafa.com
After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing - Endpoints News
After failed deal, Rallybio announces new merger; New Haven HQ to close - Hartford Business Journal
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio - Pharmaceutical Executive
Rallybio to Merge With Avenzo Therapeutics in Oncology-Focused Reverse Merger Backed by $215 Million Financing - citybiz
Rallybio swerves past Candid pothole to land deal with Avenzo - Fierce Biotech
Rallybio to acquire Avenzo in $215 million merger deal By Investing.com - Investing.com South Africa
Rallybio to acquire Avenzo in $215 million merger deal - Investing.com
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement - Business Wire
Rallybio amends employment and separation agreements for Stephen Uden, Jonathan Lieber and Steven Ryder - TradingView
Rallybio (RLYB) to combine with Avenzo; $215M concurrent financing backing deal - Stock Titan
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):